Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩14,180, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years. Valuation Update With 7 Day Price Move • May 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩16,140, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total returns to shareholders of 251% over the past three years. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩17,340, the stock trades at a trailing P/E ratio of 60.7x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 270% over the past three years. Reported Earnings • Mar 17
Full year 2025 earnings released: EPS: ₩286 (vs ₩336 in FY 2024) Full year 2025 results: EPS: ₩286 (down from ₩336 in FY 2024). Revenue: ₩64.9b (up 14% from FY 2024). Net income: ₩5.27b (down 15% from FY 2024). Profit margin: 8.1% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 61% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩20,600, the stock trades at a trailing P/E ratio of 59.2x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total returns to shareholders of 301% over the past three years. Announcement • Feb 25
MEDIANA Co.,Ltd, Annual General Meeting, Mar 24, 2026 MEDIANA Co.,Ltd, Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 132, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₩16,330, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total returns to shareholders of 223% over the past three years. Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩9,290, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 21x in the Medical Equipment industry in South Korea. Total returns to shareholders of 58% over the past three years. New Risk • Dec 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩145.4b market cap, or US$99.0m). Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩6,440, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 30% over the past three years. Buy Or Sell Opportunity • Dec 01
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 21% to ₩6,290. The fair value is estimated to be ₩5,199, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 8.9% over the last 3 years. Earnings per share has declined by 43%. Reported Earnings • May 18
First quarter 2025 earnings released: EPS: ₩84.00 (vs ₩154 in 1Q 2024) First quarter 2025 results: EPS: ₩84.00 (down from ₩154 in 1Q 2024). Revenue: ₩15.0b (up 1.9% from 1Q 2024). Net income: ₩1.55b (down 45% from 1Q 2024). Profit margin: 10% (down from 19% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩6,100, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 1.4% over the past three years. Reported Earnings • Mar 19
Full year 2024 earnings released: EPS: ₩336 (vs ₩547 in FY 2023) Full year 2024 results: EPS: ₩336 (down from ₩547 in FY 2023). Revenue: ₩57.0b (down 27% from FY 2023). Net income: ₩6.21b (down 30% from FY 2023). Profit margin: 11% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Announcement • Feb 22
MEDIANA Co.,Ltd, Annual General Meeting, Mar 24, 2025 MEDIANA Co.,Ltd, Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 132, donghwagongdan-ro, munmak-eup, gangwon-do, wonju South Korea Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩4,305, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total loss to shareholders of 48% over the past three years. New Risk • Nov 28
New major risk - Revenue and earnings growth Earnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₩90.9b market cap, or US$65.2m). Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩4,985, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Negligible returns to shareholders over past three years. Announcement • Nov 18
MEDIANA Co.,Ltd (KOSDAQ:A041920) announces an Equity Buyback for KRW 5,000 million worth of its shares. MEDIANA Co.,Ltd (KOSDAQ:A041920) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its common stock, pursuant to a contract with KB Securities co. Ltd. The purpose of the program is to Increase shareholder value through stock price stabilization. The program will expire on May 14, 2025. As of November 14, 2024, the company had 36,452 shares in treasury and 1,921 shares in treasury through other acquisition. Announcement • Jul 05
Jongheon Lee, Kyungsook Park, Sohee Lee, Lee Dawon, Dong-Un Kim, Inho Lee and Euihwan Kim agreed to acquire 18.11% stake in Lucid Korea Co., Ltd. from MEDIANA Co.,Ltd (KOSDAQ:A041920) for KRW 12.9 billion. Jongheon Lee, Kyungsook Park, Sohee Lee, Lee Dawon, Dong-Un Kim, Inho Lee and Euihwan Kim agreed to acquire 18.11% stake in Lucid Korea Co., Ltd. from MEDIANA Co.,Ltd (KOSDAQ:A041920) for KRW 12.9 billion on July 3, 2024. As part of consideration, KRW 12.9 billion is paid towards common equity of Lucid Korea Co., Ltd. For the period ending December 31, 2023, Lucid Korea Co., Ltd. reported total revenue of KRW 22.03 billion and net income of KRW 5.71 billion. As of December 31, 2023, Lucid Korea Co., Ltd. reported total debt of KRW 2.49 billion, total assets of KRW 35.05 billion and total common equity of KRW 32.56 billion. The expected completion of the transaction is September 3, 2024. Reported Earnings • May 18
First quarter 2024 earnings released: EPS: ₩154 (vs ₩148 in 1Q 2023) First quarter 2024 results: EPS: ₩154 (up from ₩148 in 1Q 2023). Revenue: ₩14.7b (down 19% from 1Q 2023). Net income: ₩2.82b (up 19% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 22
Full year 2023 earnings released: EPS: ₩557 (vs ₩664 in FY 2022) Full year 2023 results: EPS: ₩557 (down from ₩664 in FY 2022). Revenue: ₩78.4b (up 15% from FY 2022). Net income: ₩8.89b (down 16% from FY 2022). Profit margin: 11% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Jan 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (10% net profit margin). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₩122.3b market cap, or US$91.6m). Upcoming Dividend • Dec 20
Upcoming dividend of ₩50.00 per share at 0.7% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 17 April 2024. Payout ratio is a comfortable 9.4% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). New Risk • Nov 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 10% Last year net profit margin: 22% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (10% net profit margin). Market cap is less than US$100m (₩121.6b market cap, or US$93.7m). Announcement • Nov 22
MEDIANA Co.,Ltd announced that it expects to receive KRW 6.99999786 billion in funding MEDIANA Co.,Ltd announced a private placement of 1,083,591 common shares at the price of KRW 6,460 per share for gross proceeds of KRW 6,999,997,860 on November 20, 2023. The company will issue shares through third party allocation method. The transaction has been approved by board of directors of the company. The payment date for the transaction is January 10, 2024. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩125.7b market cap, or US$97.3m). Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩7,180, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total loss to shareholders of 7.7% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩5,750, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total loss to shareholders of 42% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩27.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 3.0% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.8%). Reported Earnings • Nov 20
Third quarter 2022 earnings released: EPS: ₩368 (vs ₩122 in 3Q 2021) Third quarter 2022 results: EPS: ₩368 (up from ₩122 in 3Q 2021). Revenue: ₩18.0b (up 60% from 3Q 2021). Net income: ₩5.87b (up 202% from 3Q 2021). Profit margin: 33% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 5% per year. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 21% share price gain to ₩5,100, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩4,605, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 5.0% over the past three years. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improved over the past week After last week's 19% share price gain to ₩7,780, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 94% over the past three years. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improved over the past week After last week's 16% share price gain to ₩6,690, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 82% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩26.97 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 15 April 2022. Payout ratio is a comfortable 7.5% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Dec 10
Investor sentiment improved over the past week After last week's 17% share price gain to ₩8,410, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 153% over the past three years. Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improved over the past week After last week's 30% share price gain to ₩6,680, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 83% over the past three years. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment improved over the past week After last week's 29% share price gain to ₩14,150, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 41% over the past three years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩10,850, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 52% over the past three years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩14,100, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 25% over the past three years. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS ₩1,311 (vs ₩786 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩67.5b (up 40% from FY 2019). Net income: ₩11.2b (up 67% from FY 2019). Profit margin: 17% (up from 14% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improved over the past week After last week's 15% share price gain to ₩13,450, the stock is trading at a trailing P/E ratio of 9.7x, up from the previous P/E ratio of 8.4x. This compares to an average P/E of 19x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 41%. Announcement • Feb 22
Mediana Co.,Ltd, Annual General Meeting, Mar 23, 2021 Mediana Co.,Ltd, Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Feb 22
New 90-day low: ₩13,050 The company is down 9.0% from its price of ₩14,350 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 6.0% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: ₩13,750 The company is down 4.0% from its price of ₩14,300 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Dec 01
Market bids up stock over the past week After last week's 21% share price gain to ₩17,300, the stock is trading at a trailing P/E ratio of 12.5x, up from the previous P/E ratio of 10.4x. This compares to an average P/E of 21x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 66%. Is New 90 Day High Low • Nov 18
New 90-day low: ₩13,900 The company is down 25% from its price of ₩18,450 on 20 August 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 6.0% over the same period. Valuation Update With 7 Day Price Move • Oct 28
Market pulls back on stock over the past week After last week's 15% share price decline to ₩14,350, the stock is trading at a trailing P/E ratio of 10.9x, down from the previous P/E ratio of 12.9x. This compares to an average P/E of 21x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 34%. Is New 90 Day High Low • Oct 27
New 90-day low: ₩13,950 The company is down 27% from its price of ₩19,100 on 29 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. Announcement • Sep 22
Kim Eung Seok and an unknown buyer acquired 7.01% stake in Mediana Co., Ltd. (KOSDAQ:A041920). Kim Eung Seok and an unknown buyer acquired 7.01% stake in Mediana Co., Ltd. (KOSDAQ:A041920) on April 22, 2015.
Kim Eung Seok and an unknown buyer completed the acquisition of 7.01% stake in Mediana Co., Ltd. (KOSDAQ:A041920) on April 22, 2015.